Evaluation of tractography-based myelin-weighted connectivity across the lifespan.
brain aging
microstructure informed tractography
myelin network architecture
myelin weighted connectome
structural connectivity
tractography
Journal
Frontiers in neuroscience
ISSN: 1662-4548
Titre abrégé: Front Neurosci
Pays: Switzerland
ID NLM: 101478481
Informations de publication
Date de publication:
2023
2023
Historique:
received:
25
05
2023
accepted:
04
12
2023
medline:
19
1
2024
pubmed:
19
1
2024
entrez:
19
1
2024
Statut:
epublish
Résumé
Recent studies showed that the myelin of the brain changes in the life span, and demyelination contributes to the loss of brain plasticity during normal aging. Diffusion-weighted magnetic resonance imaging (dMRI) allows studying brain connectivity In a group of 85 healthy controls aged between 18 and 68 years, we estimated myelin-weighted connectomes using Tractometry and MySD, and compared their modulation with age by means of three well-known global network metrics. Following the literature, our results show that myelin development continues until brain maturation (40 years old), after which degeneration begins. In particular, mean connectivity strength and efficiency show an increasing trend up to 40 years, after which the process reverses. Both Tractometry and MySD are sensitive to these changes, but MySD turned out to be more accurate. After regressing the known predictors, MySD results in lower residual error, indicating that MySD provides more accurate estimates of myelin-weighted connectivity than Tractometry.
Identifiants
pubmed: 38239829
doi: 10.3389/fnins.2023.1228952
pmc: PMC10794573
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1228952Informations de copyright
Copyright © 2024 Bosticardo, Schiavi, Schaedelin, Battocchio, Barakovic, Lu, Weigel, Melie-Garcia, Granziera and Daducci.
Déclaration de conflit d'intérêts
SiS was employed by ASG Superconductors S.p.A. MuB was an employee of Hays plc and a consultant for F. Hoffmann-La Roche Ltd. MW received research funding from Biogen for developing spinal cord MRI. The University Hospital Basel (USB), as the employer of CG, has received the following fees which were used exclusively for research support: (i) advisory board and consultancy fees from Actelion, Genzyme-Sanofi, Novartis, GeNeuro, and Roche; (ii) speaker fees from Genzyme-Sanofi, Novartis, GeNeuro and Roche; (iii) research support from Siemens, GeNeuro, Roche. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.